According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
Box Inc.: CEO, 10% Owner Aaron Levie bought 50,000 shares
Box Inc. (BOX, Financial) CEO and 10% owner Aaron Levie bought 50,000 shares during the past week at an average price of $12.61. Box was incroproated in 2005, as Box.Net Inc., a Washington corporation, and later reincorporated in 2008 under the same name as a Delaware corporation. Box has a market cap of $1.53 billion; its shares were traded at around $12.61 with a P/S ratio of 0.77. The dividend yield of Box stocks is 5.24%.
Box recently reported its second quarter 2015 financial results. Revenue was $73.5 million for the second quarter of fiscal 2016, an increase of 43% from the second quarter of fiscal 2015. Non-GAAP operating loss in the second quarter of fiscal 2016 was $32.7 million, or 45% of revenue.
Director Josh Stein bought 5,000 shares of Box stock on Oct. 9 at the average price of $12.14. Stein owns at least 50,767 shares. The price of the stock has increased by 3.87% since.
Opko Health Inc.: CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 20,000 shares
Opko Health Inc. (OPK, Financial) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 20,000 shares on Oct. 13 at an average price of $9.28. Opko Health was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics Inc. Opko Health has a market cap of $4.3 billion; its shares were traded at around $9.28 with a P/S ratio of 34.86. Opko Health had an annual average earnings growth of 9.00% over the past 10 years.
George Soros (Trades, Portfolio) owned 235,600 shares as of Dec. 31, 2014, which accounts for 0.026% of the $9.64 billion portfolio of Soros Fund Management LLC. Mario Gabelli (Trades, Portfolio) owned 11,000 shares as of Dec. 31, 2014, which accounts for 0.0006% of the $18.46 billion portfolio of GAMCO Investors.
Sr. Vice President and CFO Adam Logal bought 1,000 shares of Opko stock on Sept. 14 at the average price of $9.95. Logal owns at least 45,789 shares. The price of the stock has decreased by 6.73% since.Â
Neonode Inc.: President and CEO Bjorn Thomas Eriksson bought 52,631 shares
Neonode Inc. (NEON, Financial) President and CEOÂ Bjorn Thomas Eriksson bought 52,631 shares on Oct. 13 at an average price of $2.30. Neonode was incorporated in Delaware on Sept. 4, 1997 as SBE Inc. Neonode has a market cap of $93.210 million; its shares were traded at around $2.30 with a P/S ratio of 11.78.
Neonode recently announced its preliminary revenue for the third quarter of 2015. While the results for the quarter will not be final until earnings are fully announced in November, management expects that Neonode’s revenue will range from $2.9 million to $3.1 million for the three months ended Sept. 30, an increase of approximately 156% to 174% compared to the same period in 2014.
CFO Lars Lindqvist bought 10,000 shares of Neonode stock on Aug. 11 at the average price of $2.6. Lindqvist owns at least 35,000 shares. The price of the stock has decreased by 11.54% since.
FS Investment Corp.: CEO Michael C. Forman bought 2,831 shares
FS Investment Corp. (FSIC, Financial) CEO Michael C. Forman bought 2,831 shares on Oct. 6 at an average price of $9.73. FS Investment was incorporated under the general corporation laws of Maryland on Dec. 21, 2007, and began  operations on Jan. 2, 2009. FS Investment has a market cap of $2.36 billion; its shares were traded at around $9.73 with a P/E ratio of 14.12 and P/S ratio of 5.70. The dividend yield of FS Investment stocks is 7.64%.
Investment Committee Member Gerald Stahlecker bought 2,000 shares of FSIC stock on Oct. 14 at the average price of $9.7. Stahlecker owns at least 12,334 shares. The price of the stock has increased by 0.31% since.
Celator Pharmaceuticals Inc.: CEO Scott Thomas Jackson bought 14,450 shares
Celator Pharmaceuticals Inc. (CPXX, Financial) CEO Scott Thomas Jackson bought 14,450 shares on Oct. 6 at an average price of $1.80. Celator Pharmaceuticals was founded in 1999. The company is a pharmaceutical company developing new and more effective therapies to treat cancer. Celator Pharmaceuticals has a market cap of $60.830 million.
Celator Pharmaceuticals recently reported its second quarter 2015 financial results. Cash and cash equivalents as of June 30 were $28.5 million, compared to $32.4 million as of Dec. 31, 2014. The decrease of $3.9 million was primarily due to $9.0 million of net cash used in operating activities. Net loss was $5.0 million and $9.7 million for the three and six months ended June 30 as compared to $4.8 million and $9.1 million for the same periods in 2014.
VP and CFO Fred M. Powell bought 13,700 shares of Celator Pharmaceuticals stock on Oct. 5 at the average price of $1.78. Powell owns at least 31,458 shares. The price of the stock has increased by 1.12% since.
